Proteomic analysis of mantle-cell lymphoma by protein microarray

Blood

Volumn 105, Issue 9, 2005, Pages 3722-3730

  Ghobrial, Irene M ^b   McCormick, Daniel J ^b   Kaufmann, Scott H ^b   Leontovich, Alexey A ^b   Loegering, David A ^b   Dai, Nga T ^b   Krajnik, Kelly L ^b   Stenson, Mary J ^b   Meinem, Mona F ^b   Novak, Anne J ^b   Ansell, Stephen M ^b   Witzig, Thomas E ^a  

^a Stabile 6 Research Building   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

A KINASE ANCHOR PROTEIN 1; CD19 ANTIGEN; CHAPERONE; CITRON RHO INTERACTING KINASE; HEAT SHOCK PROTEIN 10; HEAT SHOCK PROTEIN 90; POLYPEPTIDE; PROTEIN MDM2; PROTEIN PHOSPHATASE 5; REGULATOR OF CHROMOSOME CONDENSATION 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL CYCLE; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MANTLE CELL LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS;

EID: 20944433868     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-10-3999     Document Type: Article

References (38)

1. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067-2078.
2. Kurtin, PM. Mantle cell lymphoma. Adv Anat Pathol.1998;5:376-398.
3. Yatabe Y, Suzuki R, Matsuno Y, et al. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. Pathol Int. 2001;51:747-761.
4. Katz RL, Wojcik EM, el-Naggar AK, Ordonez NG, Johnston DA. Proliferation markers in nonHodgkin's lymphoma: a comparative study between cytophotometric quantitation of Ki-67 and flow cytometric proliferation index on fine needle aspirates. Anal Quant Cytol Histol. 1993;15:179-186.
5. Weisenburger D, Vose JM, Greiner TC, et al. Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Amer J Hematol. 2000;64:190-196.
6. Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer. 1998;34:329-336.
7. Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16:1922-1930.
8. Bodrug SEW, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13:2124-2130.
9. Stilgenbauer S, Schaffner C, Winkler D, et al. The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol. 2000;11(suppl 1):127-130.
10. Martinez NC, Algara P, Rodriguez A, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res. 2003;63:8226-8232.
11. Antonucci FC, Parolini C, Hamdan M, Astner H, Righetti PG. Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis. 2003;24:2376-2385.
12. Hamdan M, Righetti PG. Assessment of protein expression by means of 2-D gel electrophoresis with and without mass spectrometry. Mass Spectrom Rev. 2003;22:272-284.
13. Zhu H, Snyder M. Protein chip technology. Curr Opin Chem Biol. 2003;7:55-63.
14. Meeker T, Sellers W, Harvey R, et al. Cloning of the t(11;14)(q13;q32) translocation breakpoints from two human leukemia cell lines. Leukemia. 1991;5:733-737.
15. BD Biosciences. Antibody microarray analysis workbook, http://bioinfo2.clontech.com/abinfo/array-list-action.do. Accessed January 7, 2005.
16. Svingen P, Karp JE, Krajewski S, et al. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood. 2000;96:3922-3931.
17. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1:304-313.
18. Svingen PA, Loegering DA, Meng XW, et al. Components of the cell death machine and drug sensitivity of the NCI cell line panel. Clinical Cancer Res. 2004;10:6807-6820.
19. Eischen C, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13:2658-2669.
20. Alt J, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 2003;22:1442-1450.
21. Watanabe T, Ichikawa A, Saito H, Hotta T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma. 1996;21:391-397.
22. Pagnano K, Vassallo J, Lorand-Metze I, Costa FF, Saad ST. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas [erratum published in: Am J Hematol. 2001;67:279]. Am J Hematol. 2001;67:84-92.
23. Pagnano K, Vassallo J, Lorand-Metze I, Costa FF, Saad ST. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas [erratum published in: Am J Hematol. 2001;67:279]. Am J Hematol. 2001;67:84-92.
24. Lindstrom M, Klangby U, Wiman KG. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene. 2001;20:2171-2177.
25. Moller M, Nielsen O, Pedersen NT. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology. 2002;41:322-330.
26. Solenthaler M, Matutes E, Brito-Babapulle V, Morilla R, Catovsky D. p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica. 2002;87:1141-1150.
27. Bischoff F, Ponstingl H. Mitotic regulator protein RCC1 is complexed with a nuclear ras-related polypeptide. Proc Natl Acad Sci USA. 1991;88:10830-10834.
28. Bischoff F, Ponstingl H. Catalysis of guanine nucleotide exchange on Ran by the mitotic regulator RCC1. Nature. 1991;354:80-82.
29. Dasso M, Nishitani H, Kornbluth S, Nishimoto T, Newport JW. RCC1, a regulator of mitosis, is essential for DNA replication. Mol Cell Biol. 1992;12:3337-3345.
30. Ren M, Drivas G, D'Eustachio P, Rush MG. Ran/TC4: a small nuclear GTP-binding protein that regulates DNA synthesis. J Cell Biol. 1993;120:313-323.
31. Berger A, Tang G, Alexander HR, Libutti SK. Endothelial monocyte-adivating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis. J Immunother. 2000;23:519-527.
32. Murray J, Heng YM, Symonds P, et al. Endothelial monocyte-activating polypeptide-II (EMAP-II): A novel inducer of lymphocyte apoptosis. J Leukoc Biol. 2004;75:772-776.
33. Murray J, Symonds F, Ward W, et al. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II- dependent mechanism. J Immunol. 2004;172:274-281.
34. Wera S, Hemmings BA. Serine/threonine protein phosphatases. Biochem J. 1995;311(pt 1):17-29.
35. Xu W, Yuan X, Jung YJ, et al. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res. 2003;63:7777-7784.
36. Satinover D, Leach CA, Stukenberg PT, Brautigan DL. Activation of Aurora-A kinase by protein phosphatase inhibitor-2, a bifunctional signaling protein. Proc Natl Acad Sci USA. 2004;101:8625-8630.
37. Di Cunto F, Calautti E, Hsiao J, et al. Citron rho-interacting kinase, a novel tissue-specific ser/thr kinase encompassing the Rho-Rac-binding protein Citron. J Biol Chem. 1998;273:29706-29711.
38. Ridley A. Rho proteins and cancer. Breast Cancer Res Treat. 2004;84:13-19.